Abstract

Leukemia stem cells (LSC), which are insensitive to tyrosine kinase inhibitors (TKI), are an important source of TKI resistance and disease relapse in chronic myelogenous leukemia (CML). Obstacles to eradicating LSCs include limited understanding of the regulation network of LSCs. The current study aimed to examine the interplay between NF-κB and FOXM1/β-catenin, and the effect of its chemical intervention on CML LSCs. The interplay between NF-κB and FOXM1/β-catenin was analyzed by reciprocal coimmunoprecipitation (co-IP) and chromatin immunoprecipitation (ChIP) assay in CML cells. The effect of disturbing NF-κB and FOXM1/β-catenin by niclosamide on the self-renewal capacity and survival of LSCs was evaluated in vitro in human primary CML CD34+ cells and in vivo in CML mice. Reciprocal co-IP experiments showed physical interaction of p65 and FOXM1. p65 promoted transcription of FOXM1 gene. ChIP assay revealed recruitment of p65 on the promoter of FOXM1 gene. Conversely, FOXM1 and β-catenin positively regulated the nuclear translocation and transcriptional activity of NF-κB in CML cells. Niclosamide disrupted the positive feedback loop between NF-κB and FOXM1/β-catenin, thereby impairing the self-renewal capacity and survival of CML LSCs. Niclosamide decreased the long-term engraftment of human CML LSCs in NOD-SCID IL2Rγ chain-deficient (NOG) mice, and prolonged the survival of CML mice. Interaction of p65 with FOXM1/β-catenin is critical in CML and its disruption by niclosamide eradicates LSCs. These findings may improve the understanding of a self-renewal regulatory mechanism of LSCs and offer a rationale-based approach to eliminate LSCs in CML. Clin Cancer Res; 23(3); 789-803. ©2016 AACR.

Highlights

  • Chronic myelogenous leukemia (CML) arises from hematopoietic stem cells (HSC) malignantly transformed by the BCRABL oncogene

  • Interaction of p65 with forkhead box M1 (FOXM1)/b-catenin is critical in chronic myelogenous leukemia (CML) and its disruption by niclosamide eradicates Leukemia stem cells (LSC)

  • These findings may improve the understanding of a self-renewal regulatory mechanism of LSCs and offer a rationale-based approach to eliminate LSCs in CML

Read more

Summary

Introduction

Chronic myelogenous leukemia (CML) arises from hematopoietic stem cells (HSC) malignantly transformed by the BCRABL oncogene. Treatment with a tyrosine kinase inhibitor (TKI) imatinib mesylate achieved remission in more than 80% of patients with CP CML and significantly prolonged the event-free survival of CML patients harboring the wild-type BCR-ABL [3]. Acquired resistance to imatinib is a challenge in CML treatment. Point mutations (e.g., T315I, G250E, and E255K/V) in BCR-ABL are major causes of imatinib-resistance [4]. The second-generation TKIs, can achieve good clinical response in most CML patients harboring most mutant isoforms of BCR-ABL except T315I [5]. A third-generation TKI, has been approved for treatment in imatinib-resistant CML patients harboring T315I BCR-ABL despite its potential cardiotoxicity [6, 7]. Acquired mutation resistance to imatinib is becoming a manageable clinical issue with these novel TKIs

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call